Antidepressant escitalopram more effective at preventing relapse, analysis finds
By Michelle Roberts · Nov 10, 2026, 6:17 PM CST
Three pills came top and outperformed Prozac for preventing relapse in a large number of patients.
Excerpt shown under fair-use limits. Full text remains with the original publisher.
People in this coverage
Explore their history and attributable record. Being mentioned does not imply endorsement.
Layer 1 · Claims & fact checks
AI analysisLayer 3 · Reporting analysis
AI analysisComparative FramingThe article frames escitalopram's performance by directly comparing it to a well‑known competitor, implying superiority without providing data.
Lack of EvidenceThe claim is made without citing any study, author, journal, or statistical results, leaving the assertion unsupported.
Sensational LanguageThe phrasing uses vague, superlative language that suggests a definitive ranking without substantiation.
Context
AI analysisMissing context
The article does not provide information about the study design, sample size, statistical significance, duration of treatment, patient population, or any potential side‑effects, which are essential to evaluate the claim of superiority.
Important context
Escitalopram and Prozac (fluoxetine) are both selective serotonin reuptake inhibitors (SSRIs) commonly used to treat depression. Relapse prevention studies typically compare rates of depressive episode recurrence over months or years and must control for dosage, adherence, and comorbid conditions.
Opinion vs. reporting
AI analysisThe piece reads more like a promotional claim than objective reporting; it presents a conclusion without citing evidence, methodology, or expert commentary.